A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non‐small cell lung cancer
暂无分享,去创建一个
[1] P. Duffey,et al. The calculation of actual or received dose intensity: a comparison of published methods. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Biggi,et al. Detection of suspected primary lung cancer by scintigraphy with indium-111-anti-carcinoembryonic antigen monoclonal antibodies (type F023C5) , 1991, Journal of Nuclear Medicine.
[3] F. Guidi,et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Buccheri. Chemotherapy and survival in non-small cell lung cancer. The old vexata questio. , 1991, Chest.
[5] C. Haskell. Chemotherapy and survival of patients with non-small cell lung cancer. A contrary view. , 1991, Chest.
[6] E. Vokes,et al. Chemotherapy for non-small cell lung cancer. The continuing challenge. , 1991, Chest.
[7] R. Hatlevoll,et al. Symptomatic treatment versus combination chemotherapy for patients with extensive non‐small cell lung cancer , 1991, Cancer.
[8] J. von Pawel,et al. Phase III trial with and without lonidamine in non-small cell lung cancer. , 1991, Seminars in oncology.
[9] B. Teicher,et al. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. , 1991, Cancer research.
[10] F. Pannuti,et al. A phase II study on lonidamine combined with cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma (NSCBC). , 1990, Journal of chemotherapy.
[11] D. Ferrigno,et al. Further evidence in favour of chemotherapy for inoperable non-small cell lung cancer☆ , 1990 .
[12] CJ Williams,et al. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. , 1990, British Journal of Cancer.
[13] M. De Gregorio,et al. Phase II study of lonidamine in non-small cell lung cancer: final report. , 1990, British Journal of Cancer.
[14] R. Figlin,et al. Supportive care versus supportive care and combination chemotherapy in metastatic non‐small cell lung cancer. Does chemotherapy make a difference? , 1989, Cancer.
[15] G. Giaccone,et al. Lonidamine versus Polychemotherapy in Advanced Non-Small-Cell Lung Cancer. A Preliminary Analysis , 1989, Tumori.
[16] A. Curcio,et al. Continuation of chemotherapy versus supportive care alone in patients with inoperable non‐small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study , 1989, Cancer.
[17] M. Rinaldi,et al. Chemotherapy/radiation therapy plus/minus lonidamine in the treatment of non-small cell lung cancer (limited disease): preliminary results. , 1988, Seminars in oncology.
[18] R. Souhami,et al. Chapter 1 The first international workshop on small cell lung cancer antigens , 1988 .
[19] J L Pater,et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] B. Silvestrini,et al. In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin. , 1986, Anticancer research.
[21] M. Staquet,et al. Randomized Trials in Cancer: A Critical Review by Sites , 1986 .
[22] A. Alfieri,et al. Potentiation of radiation effects on two murine tumors by lonidamine. , 1986, Cancer research.
[23] J. Sculier,et al. Progress in chemotherapy of non-small cell lung cancer. , 1984, European journal of cancer & clinical oncology.
[24] Chahinian Ap. Conventional agents in lung cancer. , 1984 .
[25] B. Silvestrini,et al. Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems. , 1983, British Journal of Cancer.
[26] M Lavandier,et al. Benefits of polychemotherapy in advanced non‐small‐cell bronchogenic carcinoma , 1982, Cancer.
[27] B. Silvestrini,et al. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. , 1981, Cancer research.
[28] B. Silvestrini,et al. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. , 1981, Journal of the National Cancer Institute.
[29] A. Teirstein,et al. Chemotherapy for bronchogenic carcinoma. Methotrexate, doxorubicin, cyclophosphamide, and lomustine. , 1977, JAMA.
[30] R. A. Green,et al. Alkylating agents in bronchogenic carcinoma. , 1969, The American journal of medicine.
[31] A. Curcio,et al. Combination chemotherapy with methotrexate, adriamycin, cyclophosphamide and CCNU (MACC) for nonsmall cell lung cancer. 4-year experience with 92 patients. , 1989, Oncology.
[32] G. Scagliotti,et al. Chronic administration of lonidamine in untreated non-small cell lung cancer of stage III M0-1. , 1989, Chemotherapy.
[33] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[34] Edwin Silverberg,et al. Cancer statistics, 1988 , 1988, CA: a cancer journal for clinicians.
[35] L. Sobin,et al. TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.
[36] A. Floridi,et al. Kinetics of inhibition of mitochondrial respiration by antineoplastic agent lonidamine , 1986 .
[37] A. Chahinian. Conventional agents in lung cancer. , 1984, Cancer treatment reports.
[38] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[39] H. Hansen,et al. Commentary: current status of chemotherapy for non-small cell lung cancer. , 1981, Cancer treatment reports.
[40] T. E. Walsh. Reporting results. , 1969, Archives of otolaryngology.
[41] O. Auerbach. Histological Typing Of Lung Tumors , 1968 .
[42] D. Karnofsky. The clinical evaluation of chemotherapeutic agents in cancer , 1949 .